---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-020070"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:34:28.394205+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q4 net loss $19.8M; cash $151.4M; ATI-052 POC trials underway

## Summary
- Net loss of $19.8M in Q4 2025 vs $96.6M in Q4 2024; full year net loss $64.9M vs $132.1M.
- Total revenue $1.3M in Q4 2025 vs $9.2M prior year; decrease due to 2024 Lilly milestone.
- Cash, equivalents and marketable securities $151.4M as of Dec 31, 2025; cash runway into H2 2028.
- Interim Phase 1a data for anti-TSLP/IL-4Rα bispecific ATI-052 support rapid advancement; Phase 1b POC trials in AD and asthma initiated.
- IND filing for lead ITK inhibitor ATI-9494 expected H2 2026; ATI-2138 showed hair regrowth in alopecia model.

## SEC filing metadata
- accession: 0001104659-26-020070
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/0001104659-26-020070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/acrs-20260226x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-020070
- JSON: https://secwatch.observer/filing/0001104659-26-020070.json
- Plain text: https://secwatch.observer/filing/0001104659-26-020070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.